The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Onkowissen; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva; Viatris
Speakers' Bureau - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Onkowissen; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
Travel, Accommodations, Expenses - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Celgene; Clinsol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Onkowissen; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva; Viatris; ZEISS
(OPTIONAL) Uncompensated Relationships - West German Study Group
Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).
 
Lisa Katharina Katharina Richters
No Relationships to Disclose
 
Oleg Gluz
Stock and Other Ownership Interests - West German Study Group
Honoraria - AstraZeneca; Celgene; Genomic Health/Exact Sciences; NanoString Technologies; Novartis; Pfizer; Roche
Consulting or Advisory Role - Celgene; Genomic Health/Exact Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Nana Weber-Lassalle
No Relationships to Disclose
 
Matthias Christgen
No Relationships to Disclose
 
Heinz Haverkamp
No Relationships to Disclose
 
Sherko Kuemmel
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Roche/Genentech; SOMATEX; Sonoscape
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche; Sonoscape
(OPTIONAL) Uncompensated Relationships - West German Study Group
 
Mohamad Kayali
No Relationships to Disclose
 
Ronald E. Kates
Stock and Other Ownership Interests - West German Study Group (I)
Honoraria - Amgen (I); AstraZeneca (I); Genomic Health (I); Novartis (I); Pfizer (I); Pierre Fabre (I); Roche (I); Zodiac Pharma (I)
Consulting or Advisory Role - Agendia (I); AstraZeneca (I); Celgene (I); Daiichi Sankyo (I); Lilly (I); Merck Sharp & Dohme (I); Novartis (I); Odonate Therapeutics (I); Pfizer (I); Pierre Fabre (I); Roche/Genentech (I); Sandoz (I); Seagen (I); West German Study Group
Research Funding - Lilly (I); Merck Sharp & Dohme (I); Novartis (I); Pfizer (I); Roche/Genentech (I)
 
Eva-Maria Grischke
No Relationships to Disclose
 
Michael Braun
Honoraria - AstraZeneca; Exact Sciences; Novartis; Pfizer; Roche; Teva
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Novartis; Puma Biotechnology; Roche
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Medac; Novartis; Roche
 
Mathias Warm
No Relationships to Disclose
 
Rachel Wuerstlein
No Relationships to Disclose
 
Corinna Ernst
Stock and Other Ownership Interests - Fresenius
 
Monika Karla Graeser
Stock and Other Ownership Interests - West German Study Group
 
Jan Hauke
No Relationships to Disclose
 
Ulrike Nitz
Stock and Other Ownership Interests - West German Study Group
Honoraria - Agendia; Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche/Genentech; Teva
Consulting or Advisory Role - Genomic Health; Roche
Research Funding - Agendia (Inst); Amgen (Inst); Celgene (Inst); Genomic Health (Inst); NanoString Technologies (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - Genomic Health
Travel, Accommodations, Expenses - Genomic Health; Pfizer; Roche
 
Hans Heinrich Kreipe
Honoraria - Amgen; AstraZeneca; Genomic Health; Lilly; Pfizer; Roche Pharma AG
 
Rita K. Schmutzler
Honoraria - AstraZeneca; Clovis Oncology; Janssen-Cilag; MSD; Pfizer
Consulting or Advisory Role - AstraZeneca; MSD
 
Eric Hahnen
Honoraria - AstraZeneca
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)